Guideline

COLISTIN: adult and paediatric guideline for South Africa, 2016

Quinten Labuschagne, Natalie Schellack, Andries Gous, Elmien Bronkhorst, Gustav Schellack, Lindie van Tonder, Archele Truter, Caroline Smith, Ruth Lancaster, Sonya Kolman
Southern African Journal of Infectious Diseases | Vol 31, No 1 | a95 | DOI: https://doi.org/10.4102/sajid.v31i1.95 | © 2019 Quinten Labuschagne, Natalie Schellack, Andries Gous, Elmien Bronkhorst, Gustav Schellack, Lindie van Tonder, Archele Truter, Caroline Smith, Ruth Lancaster, Sonya Kolman | This work is licensed under CC Attribution 4.0
Submitted: 15 May 2019 | Published: 31 March 2016

About the author(s)

Quinten Labuschagne, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Natalie Schellack, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Andries Gous, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Elmien Bronkhorst, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Gustav Schellack, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Lindie van Tonder, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Archele Truter, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Caroline Smith, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Ruth Lancaster, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa
Sonya Kolman, South African Society of Clinical Pharmacy (SASOCP), Pretoria, South Africa

Full Text:

PDF (180KB)

Abstract

This document was created to serve as a guideline for colistin prescribing in South Africa. Antimicrobial resistance is threatening the effective prevention and treatment of a wide variety of infections, especially those that are caused by multi-drug-resistant (MDR) gram-negative bacteria. Colistin is typically used as salvage therapy, or last-line treatment, for MDR gram-negative infections. The dosing regimen should be optimised to be therapeutic and halt the emergence of resistance, whilst minimizing toxicity. This document provides evidence-based recommendations for adult and paediatric dosing, dosing in renal impairment, and the use of combination therapy to increase synergistic effects, as well as guidelines on the reconstitution and administration of colistin. This guideline is specifically aimed at healthcare workers who routinely treat patients with MDR gram-negative infections, especially in the intensive care setting.

Keywords

Colistimethate sodium; CMS; polymyxin E; colistin guideline; multi-drug-resistant gram-negative bacteria

Metrics

Total abstract views: 10467
Total article views: 13479

 

Crossref Citations

1. Colistin utilization at a tertiary hospital in South Africa: an opportunity for antimicrobial stewardship practices
Gaalebale Prudence Matshediso, Oyewole Christopher Durojaiye, Oladele Vincent Adeniyi
Journal of Medical Microbiology   vol: 73  issue: 6  year: 2024  
doi: 10.1099/jmm.0.001840

2. Comparative Efficacy of Twice and Thrice Daily Colistin Administration in Critically Ill Patients Battling Multi-Drug Resistant Gram-Negative Infections: An Observational Study
Mohammed Valiyakath Hydross, Sameer Abdul Samad, Mahesh Balakrishna Savitri, Ashish Datt Upadhyay
Journal of Medical Microbiology and Infectious Diseases  vol: 12  issue: 1  first page: 50  year: 2024  
doi: 10.61186/JoMMID.12.1.50

3. Colistin use in a carbapenem-resistant Enterobacterales outbreak at a South African neonatal unit
Ilhaam Abrahams, Angela Dramowski, Kedisaletse Moloto, Lizel Lloyd, Andrew Whitelaw, Adrie Bekker
Southern African Journal of Infectious Diseases  vol: 38  issue: 1  year: 2023  
doi: 10.4102/sajid.v38i1.487

4. Appropriate use of colistin in neonates, infants and children: Interim guidance
Vindana Chibabhai, Adrie Bekker, Marianne Black, Despina Demopoulos, Angela Dramowski, Nicolette M. du Plessis, Veshni Pillay-Fuentes Lorente, Trusha Nana, Helena Rabie, Gary Reubenson, Reenu Thomas
Southern African Journal of Infectious Diseases  vol: 38  issue: 1  year: 2023  
doi: 10.4102/sajid.v38i1.555